DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?

DaVita (DVA) has climbed 55.6% year to date, outpacing its industry, as the market rewards better operating execution, an improved treatment-volume outlook, and growing confidence in value-based kidney care.

The company reaffirmed 2026 guidance calling for earnings growth of 50.6% on just 3.2% sales growth. That gap matters: the earnings leap rests on higher revenue per treatment and labor productivity gains rather than top-line expansion. In our interpretation, the stock is being priced on margin execution, not volume.

Risks are specific. Insurance-mix headwinds tied to the loss of ACA subsidies could pressure payer composition. Rising patient-care costs threaten the productivity story. Uncertain Medicare reimbursement policies add an external variable DaVita cannot control.

The source names no other tickers in the story, but the classifier groups DVA with GKOS, EW, and GMED. Treat that as a watchlist grouping, not evidence of shared drivers.

After a 55.6% run, the 50.6% earnings growth target is largely embedded in the price. Interpretation: any slip in revenue per treatment or labor productivity has more room to hurt than a beat has to help. Traders may prefer entries on pullbacks over chasing strength.